Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma (PET Chop)
This study is currently recruiting participants.
Verified by Alberta Cancer Board, August 2008
Sponsored by: Alberta Cancer Board
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00530179
  Purpose

The purpose of this study is to evaluate:

  1. whether an imaging test called a PET (Positron emission tomography) scan performed after two cycles of standard chemotherapy is able to identify patients who have a high cure rate after completing standard chemotherapy alone; and
  2. whether high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) when used in combination with an antibody called Rituximab results in high cure rates for those patients predicted to do poorly with standard chemotherapy by the PET scan.

Condition Intervention
Diffuse Large B Cell Lymphoma
 Procedure: FDG-PET scan after 2 cycles of standard R-CHOP
Procedure: Autologous Blood Stem Transplantation

MedlinePlus related topics: Cancer Lymphoma Nuclear Scans
Drug Information available for: Fluorodeoxyglucose F18
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma

Further study details as provided by Alberta Cancer Board:

Estimated Enrollment: 80
Study Start Date: July 2007
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-65 years
  • Diagnosis of Diffuse Large B-Cell Lymphoma
  • No more than one prior cycle of R-CHOP chemotherapy
  • Adequate cardiac function
  • No central nervous system involvement by lymphoma

Exclusion Criteria:

  • Histological diagnosis other than Diffuse Large B-cell Lymphoma
  • Pregnant or lactating females
  • Use of other anti-cancer therapies
  • Other serious illness that would compromise study participation
  • Prior malignancy
  • Prior stem cell transplant or radiotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00530179

Contacts
Contact: Douglas Stewart, M.D. 403-521-3347 douglast@cancerboard.ab.ca
Contact: Katherine Laid 403-521-3452 katherla@cancerboard.ab.ca

Locations
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T4C 2H5
Contact: Katherine Laid     403-521-3452     katherla@cancerboard.ab.ca    
Principal Investigator: Douglas Stewart, M.D.            
Sponsors and Collaborators
Alberta Cancer Board
Investigators
Principal Investigator: Douglas Stewart, M.D. Alberta Cancer Board
  More Information

Responsible Party: Tom Baker Cancer Centre ( Dr. Douglas Stewart )
Study ID Numbers: 0307003
Study First Received: September 13, 2007
Last Updated: August 13, 2008
ClinicalTrials.gov Identifier: NCT00530179  
Health Authority: Canada: Health Canada

Keywords provided by Alberta Cancer Board:
Diffuse Large B-Cell Lymphoma
Positron Emission Tomography
CHOP Chemotherapy protocol
Stem Cell Transplantation
Fluorodeoxyglucose F18

Study placed in the following topic categories:
Lymphoma, large-cell
Lymphoma, B-Cell
Lymphatic Diseases
Lymphoma, Large B-Cell, Diffuse
Immunoproliferative Disorders
 B-cell lymphomas
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services